NCT01332552 - A First Time in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Single and Repeat Doses of GSK2485852 in Chronically Infected Hepatitis C Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 14, 2011

Primary Completion Date

April 6, 2011

Study Completion Date

April 6, 2011

Conditions

Hepatitis C

Interventions

DRUG

GSK2485852 70 mg

single dose

DRUG

GSK2485852 420 mg

single dose

DRUG

placebo

single dose

DRUG

placebo

Repeat dose, once daily for 3 days

DRUG

GSK2485852 420 mg

Repeat dose, twice daily for 3 days

DRUG

GSK2485852 420 mg

Repeat dose, TIDfor 3 days

DRUG

GSK2485852 630 mg

Repeat dose, twice daily for 3 days

DRUG

GSK2485852 70 mg + Ritonavir 100mg

single dose, day 1

DRUG

GSK2485852 210 mg + Ritonavir 100mg

single dose, day 1

DRUG

GSK2485852 210 mg +Ritonavir 100mg

single dose daily for 3 days

Trial Locations (5)

32803

GSK Investigational Site, Orlando

66219

GSK Investigational Site, Lenexa

89106

GSK Investigational Site, Las Vegas

92801

GSK Investigational Site, Anaheim

08046

GSK Investigational Site, Willingboro